Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274904 | 0.87 | DPP4 (0.42) | DPP4 | |
| SCHEMBL1261353 | 0.86 | MTOR (0.49) | MTORRAF1BRAFPARP1TNKS2 | |
| SCHEMBL1261938 | 0.85 | PDE10A (0.51) | MTORGPR119RAF1BRAFPARP1 | |
| SCHEMBL1262953 | 0.85 | MTOR (0.50) | MTORRAF1BRAFPARP1TNKS2 | |
| SCHEMBL4391067 | 0.84 | MTOR (0.49) | MTORRAF1BRAFPARP1TNKS2 | |
| SCHEMBL1262536 | 0.83 | MTOR (0.46) | MTORGPR119RAF1BRAFPARP1 | |
| SCHEMBL1262006 | 0.83 | DPP4 (0.53) | MTORGPR119RAF1BRAFPARP1 | |
| SCHEMBL1262544 | 0.83 | GPR119 (0.45) | MTORGPR119RAF1BRAFPARP1 | |
| SCHEMBL1262024 | 0.82 | RAF1 (0.46) | MTORRAF1BRAFPARP1TNKS2 | |
| SCHEMBL1261149 | 0.82 | GBA1 (0.51) | MTORGPR119RAF1BRAFPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879848-B2 | good inhibition activity versus Dipeptidyl Peptidase-IV (DPP-IV); Diabetes mellitus, obesity; 3-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-butyl]-oxazolidin-2-one; compounds having an optionally substituted lactam ring structure | LG LIFE SCIENCES, LTD. (KR) | 2011-02-01 | — | — | US | disclosed |
| EP-1863812-B1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD (KR) | 2010-07-14 | — | — | EP | disclosed |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | DPP4, DPP7, DPP8 | MTOR 4255/4885GPR119 146/4885RAF1 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.